Latest News and Press Releases

Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.

Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.

The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.

Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC

Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.

Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.

All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...

Biora has entered into definitive agreements for the purchase and sale of 5,454,548 shares of common stock.

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.